• Publications
  • Influence
AIM: To evaluate the long-term results of conventional chemoradiotherapy and laparoscopic mesorectal excision in rectal adenocarcinoma patients without adjuvant therapy. METHODS: Patients withExpand
  • 3,834
  • 168
  • PDF
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.
BACKGROUND Imatinib, a selective inhibitor of the BCR-ABL tyrosine kinase, produces high response rates in patients with chronic-phase chronic myeloid leukemia (CML) who have had no response toExpand
  • 3,211
  • 134
  • PDF
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.
Advances in chronic myeloid leukemia treatment, particularly regarding tyrosine kinase inhibitors, mandate regular updating of concepts and management. A European LeukemiaNet expert panel reviewedExpand
  • 1,406
  • 115
  • PDF
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.
BACKGROUND The cause of chronic myeloid leukemia (CML) is a constitutively active BCR-ABL tyrosine kinase. Imatinib inhibits this kinase, and in a short-term study was superior to interferon alfaExpand
  • 3,082
  • 113
  • PDF
Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.
PURPOSE To review and update the European LeukemiaNet (ELN) recommendations for the management of chronic myeloid leukemia with imatinib and second-generation tyrosine kinase inhibitors (TKIs),Expand
  • 1,162
  • 82
  • PDF
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.
BACKGROUND Chronic myelogenous leukemia (CML) is caused by the BCR-ABL tyrosine kinase, the product of the Philadelphia chromosome. Imatinib mesylate, formerly STI571, is a selective inhibitor ofExpand
  • 1,971
  • 68
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.
The introduction of imatinib mesylate (IM) has revolutionized the treatment of chronic myeloid leukemia (CML). Although experience is too limited to permit evidence-based evaluation of survival, theExpand
  • 1,186
  • 64
  • PDF
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.
BACKGROUND Resistance to imatinib mesylate can occur in chronic myelogenous leukemia (CML). Preclinical in vitro studies have shown that nilotinib (AMN107), a new BCR-ABL tyrosine kinase inhibitor,Expand
  • 1,207
  • 62
  • PDF
Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.
BACKGROUND In a randomized trial, 1106 patients with chronic myeloid leukemia (CML) in chronic phase were assigned to imatinib or interferon alfa plus cytarabine as initial therapy. We measuredExpand
  • 1,231
  • 56
  • PDF
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders
Abnormalities of chromosome 7q are common in myeloid malignancies, but no specific target genes have yet been identified. Here, we describe the finding of homozygous EZH2 mutations in 9 of 12Expand
  • 964
  • 53